Testing a new drug combo for advanced stomach or esophageal cancer
Treatments studied
Part of Cancer clinical trials.
This study tests whether adding a targeted drug, fruquintinib, to the chemotherapy trifluridine/tipiracil works better than the chemotherapy alone for stomach or esophageal cancer that has spread. It's for people who have already tried a few treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stomach or esophageal adenocarcinoma that has spread to other parts of your body.
- You have already tried 2 or 3 separate chemotherapy treatments (including drugs like platinum, fluoropyrimidine, irinotecan, or taxane).
- You are able to be up and about with little or no help (WHO performance status 0–1).
- You have not had a heart attack, stroke, or serious heart condition in the last 6 months.
- You have not taken the study drugs (trifluridine/tipiracil, fruquintinib, regorafenib, or similar VEGFR inhibitors) before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of fruquintinib (a pill that blocks blood vessel growth), sintilimab (an immunotherapy), and targeted radiation for people with stomach or GEJ cancer that has only a few new spots after at least one prior treatment. The goal is to see if this triple approach helps control the cancer better than standard options.
This trial tests a combination of targeted therapy (fruquintinib), chemotherapy (nab-paclitaxel), and two immunotherapies (iparomlimab and tuvonralimab) for people with advanced stomach or gastroesophageal junction cancer whose first treatment with a PD-1/PD-L1 inhibitor stopped working. The goal is to see if this new combination can shrink tumors and improve outcomes.
This trial tests a combination of two drugs, fruquintinib and TAS102, for people with advanced stomach cancer that has stopped responding to at least one prior chemotherapy. The goal is to see if this new combination can help shrink tumors or slow the cancer's growth.
This trial tests a combination of two targeted drugs (fruquintinib and sintilimab) plus standard chemotherapy for people with advanced stomach or gastroesophageal junction cancer that has not been treated before. The goal is to see if this combination can help shrink or control the cancer.
This trial tests a combination of an oral targeted therapy (fruquintinib), an immunotherapy (PD-1 inhibitor), and chemotherapy (FOLFOX) as the first treatment for advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery. The goal is to see if this triplet therapy helps control the cancer better than standard treatments.
This trial tests a combination of three drugs (fruquintinib, sintilimab, and CAPEOX chemotherapy) as a first treatment for advanced stomach or gastroesophageal cancer. The goal is to see if this combination helps slow or shrink the tumor.
Hear when a new Metastatic Oesogastric Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.